Literature DB >> 22316657

Extracorporeal cardiopulmonary support may be an efficient rescue of patients after massive pulmonary embolism. An experimental porcine study.

Benedict Kjærgaard1, Bodil Steen Rasmussen, Susanne de Neergaard, Lars Hvilsted Rasmussen, Søren Risom Kristensen.   

Abstract

INTRODUCTION: Treatment of massive pulmonary embolism leading to cardiac arrest is controversial but restitution of circulation within a shorter time is crucial. Cardiopulmonary support and therapeutic hypothermia is an option for cardiac arrest and could be used to treat massive PE. However, hypothermia may influence the effect of the ongoing intrinsic fibrinolysis.
OBJECTIVES: To establish a porcine model of massive pulmonary embolism, to show that cardiopulmonary support can rescue pigs with massive pulmonary embolism and to examine the effect of hypothermia on fibrinolysis.
METHODS: Pigs ~80 kg were anesthetised and prepared for cardiopulmonary support. Repetitive injections of preformed blood thrombi into the right atrium were done until cardiac arrest. Cardiopulmonary support was established and eighteen pigs were randomised into 3 groups: Normothermia (38-39 °C); hypothermia (33-34 °C); or medication with recombinant tissue plasminogen activator. After three hours the pigs were weaned from cardiopulmonary support, and after 15 minutes with spontaneous circulation assassinated and autopsied. Remaining thrombi in the lungs were weighed.
RESULTS: The development of fatal pulmonary embolism was highly reproducible. All 18 pigs could be weaned from cardiopulmonary support and survived more than 15 minutes. The amount of remaining thromboemboli was substantial in all groups and not significantly different between groups. Normothermic group 20.0 ± 2.2 g, Hypothermic group 17.0 ± 3.7 g, and rt-PA group 14.3 ± 3.2 g.
CONCLUSIONS: Cardiopulmonary support could rescue pigs with massive pulmonary embolism. Hypothermia did not reduce the emboli but may for other reasons be beneficial. The optimal additional treatment is still unknown but treatment modalities can be tested in this model.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22316657     DOI: 10.1016/j.thromres.2012.01.007

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Comparison of isoflurane and α-chloralose in an anesthetized swine model of acute pulmonary embolism producing right ventricular dysfunction.

Authors:  Daren M Beam; Evandro M Neto-Neves; William B Stubblefield; Nathan J Alves; Johnathan D Tune; Jeffrey A Kline
Journal:  Comp Med       Date:  2015-02       Impact factor: 0.982

2.  In-Hospital Outcome in Patients Underwent Extracorporeal Membrane Oxygenation in Life-Threatening High-Risk Pulmonary Embolism.

Authors:  Jung Hyun Choi; Sang Yeub Lee; Yong Hyun Park; Jae-Hyeong Park; Kye Hun Kim
Journal:  Int J Heart Fail       Date:  2020-05-27

3.  Recent advances in the management of pulmonary embolism: focus on the critically ill patients.

Authors:  Guy Meyer; Antoine Vieillard-Baron; Benjamin Planquette
Journal:  Ann Intensive Care       Date:  2016-03-03       Impact factor: 6.925

4.  Blood-sparing removal technique of extracorporeal membrane oxygenation circuit in a Jehovah Witness patient: Case report.

Authors:  Sang Min Park; Bom Lee; Christopher Y Kim
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

5.  Percutaneous mechanical thrombectomy in patients with high-risk pulmonary embolism and contraindications for thrombolytic therapy.

Authors:  Matjaz Bunc; Klemen Steblovnik; Simona Zorman; Peter Popovic
Journal:  Radiol Oncol       Date:  2020-02-14       Impact factor: 2.991

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.